Author: Pop, E.

Source: Current Pharmaceutical Design, Volume 6, Number 13, 1 September 2000 , pp. 1347-1359(13)

Publisher: Bentham Science Publishers

Abstract:

Unlike natural cannabinoids which belong to the 6aR - trans series, the synthetic dexanabinol (HU-211), a 6aS-trans enantiomer, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, dexanabinol demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivatives, including water soluble derivatives and congeners of dexanabinol.

Keywords: Nonpsychotropic Synthetic Cannabinoids; 6aR - trans series; synthetic dexanabinol (HU-211); a 6aS-trans enantiomer; cannabimimetic activity; neuroprotective properties; therapeutic agent; 6aS-trans cannabinoids; Delta 9 tetrahydrocannabinol (THC); 6aS-trans enantiomeric series; noncompetitive N-methyl-D-aspartate (NMDA); tumor necrosis factor (TNF alpha); NMDA; Structures of dexanabinol (1) and HU-210 (2); DEXANABINOL; PM3; dexanabinol; Glycinate; substituted glycinate esters; Hetrocyclic nitrogen containing esters; Phenolic ester; Phosphate esters; Hemiesters; Pyridine 3 carboxylates; NMDA Receptor Binding; 6aS trans cannabinoids; Lactate dehydrogenase (LDH); NMDA Receptor binding properties; Novel 6aS trans cannabinoids; Gas or liquid chromatographic mass spectrometry (G

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612003399446

Publication date: 2000-09-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Pop, E.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers